98%
921
2 minutes
20
Alterations in extracellular matrix (ECM) architecture and stiffness represent hallmarks of cancer. Whether the biomechanical property of ECM impacts the functionality of tumor-reactive CD8 T cells remains largely unknown. Here, we reveal that the transcription factor (TF) Osr2 integrates biomechanical signaling and facilitates the terminal exhaustion of tumor-reactive CD8 T cells. Osr2 expression is selectively induced in the terminally exhausted tumor-specific CD8 T cell subset by coupled T cell receptor (TCR) signaling and biomechanical stress mediated by the Piezo1/calcium/CREB axis. Consistently, depletion of Osr2 alleviates the exhaustion of tumor-specific CD8 T cells or CAR-T cells, whereas forced Osr2 expression aggravates their exhaustion in solid tumor models. Mechanistically, Osr2 recruits HDAC3 to rewire the epigenetic program for suppressing cytotoxic gene expression and promoting CD8 T cell exhaustion. Thus, our results unravel Osr2 functions as a biomechanical checkpoint to exacerbate CD8 T cell exhaustion and could be targeted to potentiate cancer immunotherapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cell.2024.04.023 | DOI Listing |
Infect Agent Cancer
July 2025
Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Via Mariano Semmola, 52, Naples, Italy.
We have previously reported that microorganism-associated antigens (MAAs) share high sequence and conformational homology with tumor-associated antigens (TAAs) as well as T cells cross-react with homologous MAA/TAA pairs. More recently, we have also shown that the SARS-CoV-2 preventive vaccine, besides the humoral response, is able to elicit also a T cell response which cross-react with homologous TAAs. In the present study we analyzed the mandatory pediatric vaccines, namely the hexavalent vaccine (Diphtheria, Tetanus, Pertussis (whooping cough), Polio, Haemophilus influenzae type b (Hib), Hepatitis B) and the MMR (measles, mumps and rubella), and the chickenpox vaccine.
View Article and Find Full Text PDFJ Immunother Cancer
July 2025
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Background: Cancer immunotherapy includes vaccines generated through distinct approaches, each with advantages and limitations. Those made of autologous or allogeneic whole cells do not require prior identification of antigens, that is, immunize against undetermined (agnostic) tumor antigens. However, they often exhibit low adjuvanticity and modest antigenicity.
View Article and Find Full Text PDFFront Immunol
July 2025
Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, United States.
Introduction: Benign prostatic hyperplasia (BPH) is among the most common age-associated diseases in men. Prostatic immune cell infiltration is frequently observed with aging coincident with BPH; however, the contribution of age-related changes in immune cells to BPH is not clear. As T cells are the predominate immune cell in aged prostates, it is hypothesized that age-associated alterations in T cell subsets contribute to BPH symptoms.
View Article and Find Full Text PDFAngew Chem Int Ed Engl
August 2025
State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P.R. China.
Piezocatalytic therapy is a novel therapeutic strategy that uses mechanical energy to drive catalytic reactions to generate cytotoxic reactive oxygen species (ROS). However, existing materials are limited by low intrinsic catalytic efficiency and a single route to ROS production. This makes it difficult to break through the antioxidant barrier of the tumor microenvironment, which severely limits the antitumor efficacy.
View Article and Find Full Text PDFImmunotherapy
April 2025
Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Aim: The effectiveness of immunotherapy with tumor associated antigen vaccines can be enhanced by combining oncolytic viruses with immune checkpoint inhibitors. This study evaluates the efficacy of oncolytic reovirus in combination with an adenovector expressing carcinoembryonic antigen (Ad-CEA) and a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in a mouse model.
Methods: Mice bearing CEA-expressing CT26 tumor cells were immunized with Ad-CEA along with a PD-1/PD-L1 inhibitor.